Clinical trials: Platelet Inhibition
Coronary Artery Disease
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary…
- Trial name
- PRINCIPLE (NCT00357968)
- Testing
- Prasugrel, Clopidogrel
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 201 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndrome
A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
The study will compare the safety and efficacy of prasugrel, administered at different doses with clopidogrel in the treatment of Asian participants with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
- Trial name
- NCT00830960
- Testing
- Prasugrel, Clopidogrel
- Where
- 19 sites in China, South Korea and 2 more
- Volunteers
- 720 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Acute Myocardial Infarction
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
The goal of this study is to find out how fast a drug called selatogrel (ACT-246475) can prevent platelets from binding together. This study will also help to find out more about the safety of this new drug.
- Trial name
- NCT03487445
- Testing
- Selatogrel 8 mg, Selatogrel 16 mg
- Where
- 6 sites in Belgium, Israel and 1 more
- Volunteers
- 48 people
- Sponsor
- Viatris Innovation GmbH
Coronary Artery Disease
COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT
This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and Outside United States (OUS).
- Trial name
- NCT01925794
- Testing
- COBRA PzF
- Where
- 35 sites in United States, France and 5 more
- Volunteers
- 296 people
- Sponsor
- CeloNova BioSciences, Inc.
Diabetes Mellitus, Type 2
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as enteric…
- Trial name
- RITE (NCT02008942)
- Testing
- PL2200 Aspirin Capsules, Enteric-coated aspirin caplets
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- PLx Pharma
Acute Coronary Syndrome (ACS)
Maintenance of Platelet Inhibition With Cangrelor
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
- Trial name
- Bridge (NCT00767507)
- Testing
- cangrelor
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- The Medicines Company
Atherosclerosis, Acute Coronary Syndrome (ACS)
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a…
- Trial name
- Platform (NCT00385138)
- Testing
- Cangrelor, clopidogrel
- Where
- United States
- Volunteers
- 5,364 people
- Sponsor
- The Medicines Company
Acute Coronary Syndrome
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI
- Trial name
- NCT01603082
- Testing
- Ticagrelor, Clopidogrel
- Where
- 16 sites in United States
- Volunteers
- 343 people
- Sponsor
- AstraZeneca